You are here: Home > News > Misdeeds by pharmaceutical industry
Navigation

follow us on twitter like us on facebook watch us on youtub

 

 

Misdeeds by pharmaceutical industry

16-11-2006

New medicines are often tested on people in developing countries in an unethical manner. The Wemos Foundation in Amsterdam, the Netherlands, finds it scandalous that the pharmaceutical industry exploits the weak position of people in developing countries. A new report from the Dutch Centre for Research on Multinational Corporations (SOMO) documents no fewer than 22 known cases in which the rights of trial subjects have been violated.

The report was released on Friday, 17 November during an event held to mark the silver jubilee of the Wemos Foundation. Liesbeth van der Kruit took such politicians as Diederik Samsom (PvdA) and Kees Vendrik(GroenLinks) to task about this issue during the Grote Verkiezingsshow (the Great Election Show). The report describes tests that involved various well-known pharmaceutical companies such as Novo Nordisk, Pfizer, Johnson & Johnson, Novartis, AstraZeneca and GlaxoSmithKline. An example is Novo Nordisk, which tested new diabetes drugs on people in 32 countries. In India, the research was criticised because the required experiments on animals would not have been completed. The company discovered that laboratory animals developed tumours in continued animal research only, while the research on people had already started. The tests were subsequently halted.

Back in the early 1980s, Wemos conducted a successful campaign against Organon, which was selling anabolic steroids as growth promoters for undernourished children in Bangladesh. According to Wemos Director Nina Tellegen: “Sad to say, 25 years later there is still a need for Wemos to draw attention to misdeeds perpetrated by the pharmaceutical industry in developing countries. The report confirms that this is a widespread problem. Companies that engage in unethical testing in developing countries generally get away with it because the supervision in these countries is weak. It is high time the Dutch government took a stand on behalf of trial subjects in developing countries. It must deal with the pharmaceutical industry by imposing regulations and sanctions.”


 

  

SOMO coordinates the following networks and campaigns:

                  
Personal tools